Browse the evidence

Protein supplementation alone does not increase muscle strength; resistance training is an absolute prerequisite for protein to exert a synergistic effect on strength gains.

Do not expect muscle strength gains from protein supplements alone. If you are not lifting weights, increasing your protein intake will not make you stronger. Protein only amplifies the strength gains generated by resistance training.

Ultraprocessed food consumption is a primary driver of obesity due to high energy density, low satiety, and ease of overconsumption.

Reduce your intake of ultraprocessed foods (high in fats, sugars, and energy density). Focus on whole foods like fruits, vegetables, and grains to manage portion sizes and energy intake more effectively.

Low-fat diets (LFD) result in greater reductions in Total Cholesterol (TC) and Low-Density Lipoprotein (LDL) cholesterol compared to low-carbohydrate diets (LCD) over a duration of 6 to 23 months.

If your primary health concern is high LDL or Total Cholesterol, a low-fat diet (less than 30% of calories from fat) is likely more effective than a low-carb diet for lowering these specific numbers over the next 6-23 months. Note that this benefit disappears after 24 months.

After 24 months of adherence, there is no significant difference in weight loss or improvements in metabolic risk factors between low-carbohydrate diets and low-fat diets.

If you can stick to either a low-carb or low-fat diet for 2 years or more, you will likely achieve similar weight loss and metabolic improvements. The initial advantages of one over the other fade over time, so choose the one that fits your lifestyle and preferences best.

Weight loss triggers compensatory metabolic adaptations (hormonal and energy expenditure changes) that promote weight regain, making long-term maintenance difficult.

Expect that maintaining weight loss will be biologically challenging. Your body will fight back with increased hunger and decreased energy expenditure. This is normal and not your fault. Long-term success requires ongoing strategies to manage these biological drivers, such as regular self-monitoring and possibly higher protein intake to combat hunger hormones.

The weight loss efficacy of Tirzepatide is dose-dependent and increases with longer duration of treatment.

If you are taking Tirzepatide, sticking with the treatment for a longer duration and reaching the higher maintenance doses (like 15mg) will result in more significant weight loss than lower doses. The drug's effectiveness scales with the dose.

In crossover diet studies without washout periods, the order of macronutrient manipulation (specifically Low Carbohydrate vs. Low Fat) significantly affects energy balance and body composition outcomes due to carryover effects from gut adaptations.

If you are designing or interpreting a nutrition study that switches between two diets without a break, the order matters. Starting with a high-volume, high-fiber diet (like a Low Carb diet in this study) before switching to a lower-volume diet can lead to significantly greater weight loss than the reverse order, likely because the gut adapts to the volume/fiber of the first diet, reducing intake in the second. For individuals, this suggests that the sequence of dietary changes might impact long-term adherence and results, though this specific mechanism (gut adaptation to mass) is most relevant in controlled settings.

Obesity accelerates the loss of pancreatic beta-cell function and insulin sensitivity through ectopic adipose expansion, systemic low-grade inflammation, and lipotoxicity, leading to Type 2 Diabetes Mellitus (T2DM).

Obesity is not just about weight; it actively damages the body's ability to use insulin and produce it via inflammation and fat accumulation in organs like the liver and pancreas. Managing obesity is critical to preventing or delaying T2DM, but it requires addressing metabolic health, not just scale weight.

Type 2 diabetes should be managed as a component of Metabolic Dysfunction Syndrome (MDS) rather than solely as a hyperglycemic disorder, requiring holistic protection of target organs against all MDS-related metabolic disorders.

Do not treat Type 2 Diabetes as just a 'blood sugar problem.' Your risk of organ damage comes from the combination of high blood sugar, high blood pressure, high lipids, and excess weight. Effective management requires addressing all these metabolic factors together to protect your heart, kidneys, and eyes, rather than focusing on glucose alone.

Triple hormone receptor agonist retatrutide (1-12 mg weekly) significantly reduces liver fat in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), achieving near-maximal reduction (~80%) at 24 weeks with high doses (8-12 mg).

For patients with MASLD, high-dose retatrutide (8-12 mg weekly) offers a highly effective treatment to significantly reduce liver fat, often normalizing it within 24 weeks. This hormonal intervention addresses the root metabolic drivers of liver fat accumulation more potently than current GLP-1 mono-agonists.

Tirzepatide, a dual agonist of GLP-1 and GIP receptors, achieves significant body weight and glucose control in patients with obesity and type 2 diabetes.

Tirzepatide, which activates both GLP-1 and GIP receptors, is an effective treatment for obesity and type 2 diabetes, leading to significant improvements in body weight and glucose control. It represents a newer class of therapy with promising clinical results.

Multi-targeting agonists (tirzepatide and peptide 20) that activate GIPR, GLP-1R, and GCGR provide superior metabolic efficacy compared to GLP-1 mono-agonists (like semaglutide) by leveraging distinct structural binding modes and retaining glucagon receptor function.

For individuals managing Type 2 Diabetes or Obesity, newer multi-targeting therapies (like tirzepatide) that activate multiple metabolic receptors (GIP, GLP-1, and Glucagon) have demonstrated superior weight loss and glucose control compared to older GLP-1-only medications. This suggests that targeting multiple hormonal pathways simultaneously may offer better clinical outcomes than single-pathway treatments.

SSB intake is inversely correlated with national Socio-demographic Development Index (SDI) by 2018, meaning higher national development is associated with lower national SSB intake, though within lower-SDI nations, higher individual education correlates with higher intake.

If you are in a developing nation, be aware that SSB marketing often targets the educated and urban demographics. High individual education does not protect against high SSB intake in these regions; in fact, it may correlate with higher intake.

SSB intake is significantly higher in urban vs. rural areas globally (57.3% higher), with the largest disparities in Sub-Saharan Africa and South Asia, while being lower in urban areas of the Middle East/North Africa.

Urban dwellers, particularly in Africa and Asia, face higher exposure to SSBs. Focus on reducing availability and marketing in these high-density areas.

Oral semaglutide (7-14 mg/day) provides glucose-lowering and weight-loss effects comparable to subcutaneous formulations, though with lower bioavailability requiring higher doses.

If you prefer pills over injections, oral semaglutide is an option. You must take it on an empty stomach before breakfast, which requires discipline. It uses a higher dose than the shot version to compensate for lower absorption.

Ultra-processed foods drive obesity primarily through their high glycemic load and disrupted cellular structure, which accelerates digestion and hormonal response, rather than just their energy density.

Minimize ultra-processed foods, especially those high in carbohydrates. Whole foods retain cellular structures that slow digestion and blunt glycemic spikes, reducing the hormonal drive for fat storage.

Circadian misalignment and sleep loss disrupt peripheral clocks in skeletal muscle, leading to impaired mitochondrial function, reduced glucose tolerance, and increased insulin resistance.

Prioritize sleep for metabolic health. Poor sleep disrupts your body's internal clock, leading to worse blood sugar control and reduced mitochondrial efficiency. This happens even if you are eating well and exercising. Aim for 7-9 hours of quality sleep to support your metabolic function.

A 2-week ketogenic diet significantly upregulates adaptive immune pathways (T cell activation, oxidative phosphorylation) and alters microbiome amino acid metabolism, whereas a vegan diet upregulates innate immune pathways (antiviral responses, type I interferon) and erythrocyte differentiation.

Switching to a ketogenic diet for just two weeks shifts your immune system toward adaptive responses (T cells, oxidative phosphorylation), while a vegan diet shifts it toward innate/antiviral responses. This suggests diet can be used as a tool to modulate specific immune pathways, potentially relevant for managing inflammation or infection risk, though long-term disease outcomes require further study.

A ketogenic diet significantly downregulates microbial amino acid and vitamin biosynthesis pathways compared to a vegan diet, likely due to higher dietary availability of these nutrients reducing host reliance on microbiome-derived metabolites.

On a ketogenic diet, your gut bacteria produce fewer amino acids and vitamins because you are getting them directly from food. This suggests that the microbiome's role shifts based on dietary intake, and you may not need to rely on gut bacteria for these nutrients as much as on a vegan diet.

Tirzepatide's GIP receptor agonism directly enhances adipocyte glucose uptake and lipid clearance in the fed state by cooperating with insulin, contributing to reduced serum triglycerides without increasing adiposity.

Tirzepatide works partly by helping your fat cells clear sugar and fat from your blood more effectively when you eat, thanks to its GIP receptor activity. This helps lower blood fat levels without making you gain more body fat, complementing the weight loss driven by other mechanisms.

In the fasted state (low insulin), tirzepatide's GIP receptor agonism stimulates lipolysis (fat breakdown) to release stored energy, counter-regulating insulin's storage signal.

When you are not eating, tirzepatide helps your fat cells release stored fat for energy. This happens because the drug's GIP activity stimulates fat breakdown when insulin is low, ensuring your body can access energy stores during fasting periods.

Metformin (850mg twice daily) reduces the incidence of type 2 diabetes by 31% in adults with prediabetes compared to placebo, with effects persisting for up to 22 years.

If you have prediabetes and are over 60, have a BMI over 35, or had gestational diabetes, ask your doctor about Metformin. It is a proven, low-cost way to significantly lower your risk of developing full-blown diabetes, with benefits lasting for decades.

Thiazolidinediones (specifically Pioglitazone) reduce the incidence of type 2 diabetes in individuals with impaired glucose tolerance, but their use is limited by adverse effects such as weight gain, fluid retention, and increased fracture risk.

Pioglitazone can prevent diabetes, but it often causes weight gain and other side effects. It is usually not the first choice; Metformin or GLP-1 medications are typically preferred unless Pioglitazone is specifically indicated for your case.

Resistance training protocols must report within-exercise variables beyond load and repetitions—including failure status, range of motion, time under tension, and attentional focus—to accurately determine the training stimulus.

When designing or documenting a resistance training program, do not just list the weight and number of reps. You must also specify whether sets were taken to failure, the range of motion used (full or partial), the speed/tempo of each phase, and whether the athlete used an internal or external focus. This level of detail is required to replicate the stimulus and ensure the training is effective.